

# **Radiological Physics Center**

*Report to*

# **ATC Steering Committee**



**Geoffrey S. Ibbott, Ph.D.**  
**and RPC Staff**











# Mission

---

- The mission of the Radiological Physics Center is to **assure NCI and the Cooperative Groups that** institutions participating in clinical trials deliver prescribed **radiation doses that are clinically comparable and consistent**. We do this by assessing the institution's radiotherapy programs, helping the institutions implement remedial actions, assisting the study groups in developing protocols and QA procedures, and summarizing our findings for the radiation therapy community.

# RPC's QA Activities

---

-  Remote audits of machine output
-  Treatment record reviews
-  On-site dosimetry reviews
-  **Credentialing**
  -  Questionnaires, rapid reviews, benchmarks, phantoms
-  Independent recalculation of patient dose
-  Audits of Proton Therapy Centers
  -  Questionnaires, TLD audits, visits, phantoms
-  International Activities
  -  Independent remote audits

# Web-based Facility Questionnaire

All textboxes can be edited. Please verify correctness of data. Click **Submit** data with more than one records (in frames), use the according **Buttons** on

1) Institution Name:	<input type="text" value="21st Century Oncology-Englewood"/>		
Address	<input type="text" value="Englewood Radiation Therapy Regional Ctr."/>		
	<input type="text" value="571 Medical Drive"/>		
City	<input type="text" value="Englewood"/>		
State	<input type="text" value="FL"/>	Country	<input type="text" value="USA"/>
Telephone:	<input type="text" value="9414750022"/>	Extension:	<input type="text"/>
		Fax:	<input type="text"/>
Person submitting this form	<input type="text"/>		
Email	<input type="text"/>		Ph
3) Date questionnaire updated	<input type="text" value="23-Sep-2009"/>		
4) Cooperative group membership	<input type="text"/>		

# Facility Questionnaire (cont'd)

Local identifiers of unit:

Serial Number:

90

Vendor:

Varian

Model:

Clinac 18

Photon Energies:

10

Number of additional identical units:

1

Has the output of this machine been monitored with TLD within the past year (date)

7/9/2009

MLC or other beam modulator:

Uses (Check Applicable Boxes)

IMRT:

IGRT:

**B. Planning Resources Resou**  
(Click here for various resources:)

Dose Painting  
Dynamic gantry DMLC  
Helical tomotherapy  
Intensity Arc Therapy  
Rapid ARC  
Serial tomotherapy

# Facility Questionnaire (cont'd)

How do you verify field positioning relative to the patient's anatomy?

Bat ultrasound

CT

MV Ortho

MV\_Port

Other: Please describe:

How often is positioning verification done?

first treatment only


daily

other: Please describe


## 2. VERIFICATION OF DELIVERED DOSE FOR 3DCRT

Describe the method(s) used to conduct a check of the dose delivered to the target area.

# RPC Phantoms



**Pelvis (10)**




**Thorax (13)**



**H&N (31)**



**SRS Head (4)**



**Liver (2)**


# Lung Phantom and Moving Platform

QuickTime™ and a  
Photo - JPEG decompressor  
are needed to see this picture.



# Number of Phantoms Mailed per Year


- Spine
- SRS head
- Liver
- Prostate
- Lung
- H&N




**Treat phantom  
as if it were a  
patient**




Absolute  
 700,0 cGy  
 660,0 cGy  
 614,0 cGy  
 600,0 cGy  
 540,0 cGy  
 502,0 cGy  
 450,0 cGy  
 400,0 cGy  
 350,0 cGy



Absolute  
 700,0 cGy  
 660,0 cGy  
 614,0 cGy  
 600,0 cGy  
 540,0 cGy  
 502,0 cGy  
 450,0 cGy  
 400,0 cGy  
 350,0 cGy



Absolute  
 700,0 cGy  
 660,0 cGy  
 614,0 cGy  
 600,0 cGy  
 540,0 cGy  
 502,0 cGy  
 450,0 cGy  
 400,0 cGy  
 350,0 cGy






Deliver  
treatment



# RPC Compares Treated Distribution with Plan





# Phantom Results

Comparison between institution's plan and delivered dose.  
Criteria for agreement: 7% or 4 mm DTA (5%/5mm for lung)


Site	Irradiations	Pass
H&N	718	78%
Pelvis	130	82%
Lung	167*	71%
Liver	18	50%

\*Irradiated without motion. If "good" algorithm, 77% pass. If consider only 3D-CRT, 85% pass.






# Comparison: Planned vs. Delivered Distribution






# HN results grouped by TPS

Treatment planning system	Pass Rate (%)	Attempts	Criteria Failed		
			Dose	DTA	Dose and DTA
Corvus	75	32	7	0	1
Eclipse	85	114	10	4	3
Pinnacle	73	168	33	4	8
TomoTherapy	73	22	5	1	0
XiO	73	59	7	4	5
Other	79	24	3	0	2
Total		419	65	13	19





# Explanations for Failures


Explanation	Minimum # of occurrences
<b>incorrect output factors in TPS</b>	<b>1</b>
<b>incorrect PDD in TPS</b>	<b>1</b>
<b>IMRT Technique</b>	<b>3</b>
<b>Software error</b>	<b>1</b>
<b>inadequacies in beam modeling at leaf ends (Cadman, et al; PMB 2002)</b>	<b>14</b>
<b>QA procedures</b>	<b>3</b>
<b>errors in couch indexing with Peacock system</b>	<b>3</b>
<b>equipment performance</b>	<b>2</b>
<b>setup errors</b>	<b>7</b>

# RPC's QA Activities

---

- Remote audits of machine output
- Treatment record reviews
- On-site dosimetry reviews
- **Credentialing**
  - ◆ Questionnaires, rapid reviews, benchmarks, phantoms
- **Independent recalculation of patient dose**
- **Audits of Proton Therapy Centers**
  - ◆ Questionnaires, TLD audits, visits, phantoms
- **International Activities**
  - ◆ Independent remote audits

# Independent Reviews of Patient Plans



# RPC's QA Activities

---

- Remote audits of machine output
- Treatment record reviews
- On-site dosimetry reviews
- **Credentialing**
  - ◆ Questionnaires, rapid reviews, benchmarks, phantoms
- Independent recalculation of patient dose
- **Audits of Proton Therapy Centers**
  - ◆ Questionnaires, TLD audits, visits, phantoms
- **International Activities**
  - ◆ Independent remote audits

# Charged particle beams

---

- ❖ Presently 6 clinically-active US proton therapy centers
- ❖ 1 new center expected to open this year, perhaps 5 more in next 2 years
- ❖ No heavy particle beam centers anticipated today
- ❖ RPC anticipates that by 5th year of next grant cycle, will need to prepare to audit helium/carbon ion beam facilities



# Proton Facility Credentialing


---

- \* NCI Guidelines mandate –
  - \* Questionnaire - sent to facilities by QARC
    - \* Completed by 4 of 5 centers
- \* TLD monitoring
  - \* Mailed to 7 US centers + 1 Japanese center
- \* On-site dosimetry review visits
  - \* 1 visit largely completed, 3 visits under way
- \* Anthropomorphic phantom
  - \* Modified existing pelvis phantom

# RPC TLD System




# Proton Beam Monitoring




ATC Steering: Oct. 26, 2009

# Distribution of Photon Beam TLD Measurements




# Re-validation of TLD System




# Audits

---

- ❖ Evaluation of OSL for audits of proton beams will begin this summer
- ❖ Program of evaluation likely to extend into next grant cycle



# Visits: Depth Dose Measurements




# Phantoms

---


- ❖ Pelvis phantom has been developed
  - ❖ Evaluation is under way, will be completed this fall
- ❖ Lung phantom evaluation will begin this fall
  - ❖ Evaluation of materials will be considerably more complex
  - ❖ Likely to extend into next grant cycle



# Proton Pelvis Phantom





# Material Stopping Powers



# Phantom Treatment

- ❖ Treatment plan created with a prescription of 6 Gy to the prostate
- ❖ Plan delivered 3 times with film and TLD inserted in phantom
- ❖ Plan accounting for difference in patient and material SP to be delivered in near future



# TLD results



	<b>PTV Right</b>	<b>PTV Left</b>	<b>Femur Right</b>	<b>Femur Left</b>
<b>Institution Predicted Dose (cGy)</b>	600.2	600.2	247.3	243.8
<b>TLD Measured Dose (cGy)</b>	589.8	595.1	242.1	240.4
<b>Measured / Predicted Dose</b>	<b>0.983</b>	<b>0.992</b>	<b>0.979</b>	<b>0.986</b>

- ❖ PTV within 1.7% of predicted value
- ❖ Femur within 2.1% of predicted value

# Film Results

Feb. 19 2009 Trial 1

## Superior Inferior Profile - Coronal Plane



# RPC's QA Activities

---

- Remote audits of machine output
- Treatment record reviews
- On-site dosimetry reviews
- **Credentialing**
  - ◆ Questionnaires, rapid reviews, benchmarks, phantoms
- Independent recalculation of patient dose
- Audits of Proton Therapy Centers
  - ◆ Questionnaires, TLD audits, visits, phantoms
- **International Activities**
  - ◆ Independent remote audits

# International Participation

- RPC has audited international institutions that are members of US study groups, as part of routine audits
- In 2007, RPC was approached by EORTC to consider offering TLD audits to EORTC members, at cost
- Following agreement among RPC, EORTC and NCI, EORTC began recommending RPC's TLD service to their members
- Subsequent meetings between RPC, EORTC, and other groups have been held to discuss expanding auditing procedures
- RPC now auditing 156 non North-American institutions
  - Including 60 EORTC members

# International Clinical Trials

- RTOG (and several other study groups\*) are expanding trials to international participation
- Through agreements with EORTC, RPC will likely make phantoms available to international participants in NCI-sponsored clinical trials
  - Funding source yet to be determined
- Proposal for international workshops in development
- \*NCCTG and GOG, among others



# International Study Groups

- RPC has developed relationships with several international clinical trials QA offices, leading to reciprocal visits and collaborations:
- TROG – Trans-Tasman Radiation Oncology Group
- EORTC – European Organization for Research and Treatment of Cancer
- Japanese National Cancer Center:  
Outreach Radiation Oncology  
and Physics



# Irradiation of RPC Phantoms

- Through various arrangements, 18 international institutions have already irradiated RPC phantoms
- Arrangements are being discussed for providing phantoms to additional institutions in Europe, the Middle East, Australasia and Latin America
- Through agreement with the RTOG and NCI, international non-member institutions participating in RTOG trials will meet the same QA requirements as member institutions

• Questions?

